Mease PJ, Chohan S, Fructuoso FJG, et al. - Researchers conducted this randomised, double-blind, placebo-controlled, phase IIb study to test the safety and effectiveness of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA). Active PsA patients were randomised 1:1:1:1:1 to tildrakizumab 200 mg every 4 weeks (Q4W); tildrakizumab 200, 100 or 20 mg Q12W; or placebo Q4W. Patients who had been receiving tildrakizumab 20 mg or placebo were transferred to tildrakizumab 200 mg Q12W at W24; treatment continued to W52. According to results, 391/500 patients screened were randomised and treated. Other than dactylitis and enthesitis, tildrakizumab treatment significantly improved joint and skin manifestations of PsA. Treatment was usually well-tolerated through W52.